The FDA acceptance of the NDA for zidesamtinib with a clear PDUFA date creates a near-term catalyst for the stock. The strong cash position supports ongoing development and potential commercialization efforts. Traders should monitor upcoming clinical trial progress and regulatory interactions.
How the stock moved after the report
BULLISH VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Feb 26 $103.93entry
- T+1 · 9mo ago −1.91%α −1.45% · $101.95
- T+5 · 9mo ago −3.66%α −2.53% · $100.13
- T+20 · 8mo ago −5.65%α +0.75% · $98.06
- T+60 · 6mo ago −2.59%α −10.34% · $101.24
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Nuvalent reported its 2025 financial results, highlighted a strong cash position of $1.4 billion with runway into 2029, and provided updates on its drug development pipeline. Key milestones include FDA acceptance of the NDA for zidesamtinib with a PDUFA date of September 18, 2026, and plans for neladalkib NDA submission in the first half of 2026. The company also completed a $500 million public offering in November 2025.
Key Financial Metrics
Key Facts
- Cash, cash equivalents and marketable securities were $1.4 billion as of December 31, 2025
- FDA accepted NDA for zidesamtinib with PDUFA target action date of September 18, 2026
- Completed $500 million public offering of common stock in November 2025
- R&D expenses were $307.0 million for full year 2025
- Net loss was $425.4 million for full year 2025
Financial Impact
Strong financial position with $1.4 billion in cash and marketable securities, providing runway into 2029
Risk Factors
- Clinical trial results may not meet expectations
- FDA may not approve zidesamtinib or neladalkib on the expected timeline
- High R&D expenses will continue to generate net losses
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 5 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001193125-26-073304 |
| Document: nuvl-20260226.htm | 0001193125-26-073304 |
| Document: 0001193125-26-073304-index-headers.html | 0001193125-26-073304 |
| Document: 0001193125-26-073304-index.html | 0001193125-26-073304 |
| Document: 0001193125-26-073304.txt | 0001193125-26-073304 |
Track record
18 reports on NUVL
4 of 6 bullish or bearish reports moved the stock their way by T+20. Best: +21.01% at T+60 after the Apr 7, 2026 report. 4 of 7 went positive at some point.
Filters
- Jul 27, 202616w ago 15-12G Neutral 3/10 No price data
- Jul 15, 202617w ago 25-NSE Neutral 3/10 Entry $123.96 No price data
- Jul 15, 202617w ago 8-K Bullish 5/10 Entry $123.96 No price data
- Jul 8, 202618w ago Insider Cluster Neutral 3/10 Entry $123.80 No price data
- Jul 6, 202619w ago Insider Cluster Neutral 3/10 Entry $123.72 No price data
- Jun 11, 202622w ago Insider Cluster Neutral 2/10 Entry $123.25 to $123.90 ▲ +0.53% −1.25% vs SPY
- Jun 10, 202622w ago Insider Cluster Neutral 3/10 Entry $123.45 to $123.83 ▲ +0.31% −1.58% vs SPY
- Jun 9, 202622w ago 8-K Bullish 8/10 Entry $123.25 to $123.77 ▲ +0.42% −1.02% vs SPY
- May 7, 202627w ago 8-K Neutral 4/10 Entry $102.40 to $90.18 ▼ −11.93% −15.07% vs SPY
- Apr 29, 202628w ago Insider Cluster Neutral 2/10 Entry $99.10 to $107.38 ▲ +8.36% +2.90% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers